SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+1.62%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.56B
AUM Growth
+$1.56B
(+0.03%)
Cap. Flow
+$130M
Cap. Flow
% of AUM
8.34%
Top 10 Holdings %
Top 10 Hldgs %
60.82%
Holding
82
New
11
Increased
20
Reduced
11
Closed
11
Top Buys
| 1 |
Regenxbio
RGNX
|
$28.8M |
| 2 |
Xencor
XNCR
|
$21.5M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
$20.9M |
| 4 |
iRhythm Technologies
IRTC
|
$19.9M |
| 5 |
Guardant Health
GH
|
$19.3M |
Top Sells
| 1 |
AstraZeneca
AZN
|
$67.8M |
| 2 |
United Therapeutics
UTHR
|
$20M |
| 3 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$15.8M |
| 4 |
Zoetis
ZTS
|
$14.8M |
| 5 |
Exelixis
EXEL
|
$10.3M |
Sector Composition
| 1 | Healthcare | 93.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$23.1B
| $290M | 16.93% | 3,102,960 | – | – |
|
|
KRTX
2
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $256M | 14.94% | 1,953,077 | – | – |
|
3
Vera Therapeutics
VERA
$1.38B
| $77.9M | 4.55% | 2,914,776 | – | – |
|
4
Ascendis Pharma
ASND
$11.8B
| $67.2M | 3.93% | 499,824 | – | – |
|
|
JBIO
5
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $44.3M | 2.59% | 3,758,686 | – | – |
|
6
AbbVie
ABBV
$372B
| $42.2M | 2.47% | 312,018 +39,418 | +14% | +$5.34M |
|
7
Y-mAbs Therapeutics
YMAB
$388M
| $35.6M | 2.08% | 2,194,278 | – | – |
|
|
8
Regenxbio
RGNX
$451M
| $33M | 1.93% | 1,008,081 +880,488 | +690% | +$28.8M |
|
9
Travere Therapeutics
TVTX
$1.56B
| $32.3M | 1.89% | 1,040,858 +603,578 | +138% | +$18.7M |
|
|
10
United Therapeutics
UTHR
$13.8B
| $28M | 1.64% | 129,754 -92,340 | -42% | -$20M |
|
11
Heron Therapeutics
HRTX
$207M
| $26.8M | 1.56% | 2,933,351 +632,172 | +27% | +$5.77M |
|
|
CCXI
12
DELISTED
ChemoCentryx, Inc.
CCXI
| $26.6M | 1.56% | 731,222 +213,514 | +41% | +$7.77M |
|
|
BPMC
13
DELISTED
Blueprint Medicines
BPMC
| $26.3M | 1.53% | 245,182 +63,322 | +35% | +$6.78M |
|
14
Align Technology
ALGN
$10.3B
| $25.1M | 1.46% | 38,159 -8,841 | -19% | -$5.81M |
|
|
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $23.9M | 1.4% | 221,792 +64,305 | +41% | +$6.93M |
|
|
16
Guardant Health
GH
$8.41B
| $23.3M | 1.36% | 232,563 +192,563 | +481% | +$19.3M |
|
|
17
Xencor
XNCR
$580M
| $21.5M | 1.26% | +537,030 | New | +$21.5M |
|
18
Cytokinetics
CYTK
$4.23B
| $21.2M | 1.24% | 464,366 +37,734 | +9% | +$1.72M |
|
|
19
BioCryst Pharmaceuticals
BCRX
$1.74B
| $20.9M | 1.22% | +1,510,473 | New | +$20.9M |
|
20
Syndax Pharmaceuticals
SNDX
$1.41B
| $20.8M | 1.22% | 951,226 +537,385 | +130% | +$11.8M |
|
|
21
iRhythm Technologies
IRTC
$5.46B
| $19.9M | 1.16% | +168,882 | New | +$19.9M |
|
22
DexCom
DXCM
$29.5B
| $17.4M | 1.02% | 32,404 -4,862 | -13% | -$2.61M |
|
23
Protagonist Therapeutics
PTGX
$3.67B
| $16.5M | 0.96% | 482,257 +184,548 | +62% | +$6.31M |
|
|
INBX
24
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $16.1M | 0.94% | +368,679 | New | +$16.1M |
|
25
NextCure
NXTC
$13.5M
| $16M | 0.94% | 2,671,856 | – | – |
|